EE498 Cost-per-Responder Analysis of Bimekizumab Vs Other Licensed Anti-Interleukin Therapies in Psoriatic Arthritis from a UK Perspective
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.763
https://www.valueinhealthjournal.com/article/S1098-3015(23)03893-7/fulltext
Title :
EE498 Cost-per-Responder Analysis of Bimekizumab Vs Other Licensed Anti-Interleukin Therapies in Psoriatic Arthritis from a UK Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03893-7&doi=10.1016/j.jval.2023.09.763
First page :
Section Title :
Open access? :
No
Section Order :
10249